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OBJECTIVEdWe recently showed that RNA oxidation, estimated by urinary excretion of
8-oxo-7,8-dihydroguanosine (8-oxoGuo), independently predicted mortality in a cohort of
1,381 treatment-naive patients with newly diagnosed type 2 diabetes. In the present investiga-
tion, we analyzed urine collected 6 years after the diagnosis to assess the association between
urinary markers of nucleic acid oxidation and mortality in patients with established and treated
diabetes.
RESEARCH DESIGN AND METHODSdWe used data from the 970 patients who
attended the screening for diabetes complications 6 years after the diagnosis. Cox proportional
hazards regression was used to examine the relationship between urinary markers of DNA
oxidation (8-oxo-7,8-dihydro-29-deoxyguanosine [8-oxodG] [n = 938]) and RNA oxidation
(8-oxoGuo [n = 936]) and mortality.
RESULTSdDuring a median of 9.8 years of follow-up, 654 patients died. Urinary 8-oxoGuo
assessed 6 years after the diagnosis was signiﬁcantly associated with mortality. The multivariate-
adjustedhazard ratios for all-cause and diabetes-relatedmortality of patientswith 8-oxoGuo levels in
the highest quartile compared with those in the lowest quartile were 1.86 (95% CI 1.34–2.58) and
1.72 (1.11–2.66), respectively. Conversely, 8-oxodGwas not associated with mortality. In addition,
we found an association between changes in 8-oxoGuo from diagnosis to 6-year follow-up and
mortality, with increased risk in patients with an increase and decreased risk in patients with a
decrease in 8-oxoGuo.
CONCLUSIONSdThe RNA oxidation marker 8-oxoGuo is an independent predictor of
mortality in patients with established and treated type 2 diabetes, and changes in 8-oxoGuo
during the ﬁrst 6 years after diagnosis are associated with mortality.
Diabetes Care 36:669–676, 2013
The increasing prevalence of diabetestogether with the associatedmorbid-ity and mortality calls for additional
preventive and therapeutic strategies.
New biomarkers that can be used in
therapy control and risk stratiﬁcation as
an alternative to current methods are
needed and can facilitate a more individ-
ualized and sufﬁcient treatment of
diabetes. Evidence derived from both
epidemiological and mechanistic studies
suggests that oxidative stress has an im-
portant role in mediating the pathologies
of diabetes complications (1–6). Al-
though studies have shown associations
between markers of oxidative stress and
diabetes complications, the predictive
value of these markers has not been vali-
dated in large-scale prospective studies
(7,8).
A number of studies indicate that uri-
narymarkers of nucleic acid oxidation could
be useful biomarkers in diabetes. Associa-
tions between urinary excretion of the DNA
oxidation marker 8-oxo-7,8-dihydro-29-
deoxyguanosine (8-oxodG) anddiabetes or
diabetes-related quantitative traits have
been shown (8), but no similar studies
have been performed for the ribonucleo-
side counterpart 8-oxo-7,8-dihydroguano-
sine (8-oxoGuo). The current knowledge
of the prognostic importance of urinary
markers of nucleic acid oxidation is limited
to one study (9).
We previously investigated the asso-
ciation between markers of nucleic acid
oxidation and mortality in the Diabetes
Care in General Practice cohortda
population-based cohort of 1,381 patients
newly diagnosed with diabetesdand
showed that urinary excretion of the RNA
oxidation marker 8-oxoGuo measured
shortly after diagnosis of type 2 diabetes
predicted mortality independently of con-
ventional risk factors (9). It is, however, not
known whether urinary 8-oxoGuo also
predicts mortality in the established and
treated diabetic state or whether changes
in urinary 8-oxoGuo are associated with
changes in mortality.
To investigate the association between
the urinary markers of DNA (8-oxodG)
and RNA (8-oxoGuo) oxidation and mor-
tality in established and treated type 2
diabetes, we used data from the Diabetes
Care in General Practice cohort obtained 6
years after diagnosis. In addition, we
combined these data with data from the
time of diagnosis to assess the association
between changes in these markers and
mortality.
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RESEARCH DESIGN AND
METHODSdIn the Diabetes Care in
General Practice study (10), 474 general
practitioners agreed to include all subjects
on their practice list who fulﬁlled the fol-
lowing criteria: newly diagnosed diabetes
based on hyperglycemia symptoms and/
or raised blood glucose values, diagnosed
between 1 March 1989 and 28 February
1992 and aged $40 years. The diagnosis
was subsequently conﬁrmed with a single
fasting whole blood/plasma glucose value
of$7.0/8.0 mmol/L, measured in a major
laboratory. The protocol-based exclusion
criteria were life-threatening somatic dis-
ease, severemental illness, or unwillingness
to participate. After exclusion of 162 pa-
tients, the original study population consis-
ted of 1,381 newly diagnosed diabetic
patients. Based on the onset of insulin treat-
mentwithin 180 days of diagnosis, ~97.5%
were considered to have type 2 diabetes
(10). Freshly voidedmorning urine samples
were collected fromall patients at the time of
diagnosis and again at the sixth annual
screening for diabetes complications (6-
year follow-up). In the present investigation,
we used data from the 970 patients who
attended the screening. The protocol was
approvedby the ethics committee ofCopen-
hagen and Frederiksberg, and informed
consent was obtained from all patients.
Assessments
The urine samples were assayed between
2009 and 2010 for the oxidatively mod-
iﬁed guanine nucleosides 8-oxodG and
8-oxoGuo using a validated method of
ultraperformance liquid chromatography
and tandem mass spectrometry (11). For
32 (3.3%) and 34 (3.5%) patients, respec-
tively, no valid assessments of 8-oxodG
and 8-oxoGuo were obtained. 8-oxodG
and 8-oxoGuo were normalized against
urinary creatinine concentration. The as-
sessment of the remaining patient character-
istics at baseline and at 6-year follow-up has
been described previously (10). Cohabita-
tion status, education level, and height
(used in BMI calculation)were only assessed
at diagnosis.
The vital status of all the patients was
certiﬁed on 1 January 2009 through the
Danish Civil Registration System (12).
The vital status of one patient could not
be assessed because this person had emi-
grated in 1992. Diabetes-related death
was deﬁned as at least one of the following
entries in the Danish National Register of
Causes ofDeath (13): suddendeath or death
from myocardial infarction, stroke, renal
disease, hyperglycemia, hypoglycemia, or
peripheral vascular disease. The cause of
death was not recorded in the register in
three cases.
Statistical analysis
The participants were grouped according
to the quartiles of their urinary 8-oxodG
and 8-oxoGuo levels in order to examine
the associations between patient charac-
teristics at 6-year follow-up and the cor-
responding levels of oxidative stress. The
medians and interquartile ranges (for
continuous characteristics) or percen-
tages (for categorical characteristics)
were reported for each quartile, and
associations were assessed by Kruskal-
Wallis or x2 tests, respectively.
The associations between oxidative
stress and all-cause mortality and
diabetes-related mortality, respectively,
were analyzed in Cox proportional haz-
ards regression models based on time
from 6-year follow-up to death or censor-
ing. Oxidative stress was represented by
the natural logarithm of 8-oxodG and 8-
oxoGuo and by a four-class ordinal vari-
able corresponding to the quartiles of the
distribution. Two models were estimated
for each of the oxidative stress variables and
each of the outcomes: a univariate (un-
adjusted) model and a multivariate model.
Covariates included in the latter model
were age, sex, diabetes duration, smoking
status, cohabitation status, physical activ-
ity, education, BMI, presence or absence of
hypertension and of microalbuminuria,
A1C, total cholesterol, triglycerides, serum
creatinine, presence or absence of retinop-
athy and of peripheral neuropathy, history
of acute myocardial infarction and stroke,
and antidiabetes treatment.
For investigation of the inﬂuence of
changes in oxidative stress from diagnosis
to the 6-year follow-up on subsequent
mortality, two 16-class variables were cre-
ated where the classes corresponded to the
combination of the quartiles at diagnosis
and at 6-year follow-up of 8-oxodG and 8-
oxoGuo, respectively. These variables were
then used in Cox proportional hazards
models as described above to assess the
signiﬁcance of upward and downward
movements between quartiles. Only pa-
tients with a valid measurement both at
diagnosis and at assessment 6 years after
diagnosis were included in this analysis.
The proportional hazards assumption
was tested by adding the interactions
between each of the independent vari-
ables and the logarithm of time since
diagnosis to the model; a joint test of
these interactions tests the assumption.
The assumption was not violated in any of
the models.
In addition, to determine the possible
additional prognostic value of adding uri-
nary 8-oxoGuo to established biomarkers
and risk factors, we generated receiver
operating characteristic (ROC) curves for
all-cause mortality, and the areas under the
curves (AUCs) were calculated.
Reported P values are two sided. Anal-
yses were performed with SAS version 9.2.
RESULTSdTables 1 and 2 show char-
acteristics of the study participants at
6-year follow-up according to quartiles
of 8-oxodG and 8-oxoGuo. The median
age at 6-year follow-up was 69.2 (inter-
quartile range 59.9–77.3), with an equal
distribution of men and women (51.4 and
48.6%, respectively).
For both 8-oxodG and 8-oxoGuo,
participants in the highest quartiles were
older, were more often women, and had
lower levels of serum creatinine. In addi-
tion, participants in the highest quartiles of
8-oxodG had lower total cholesterol, and
those in the highest quartile of 8-oxodGhad
lower BMI than participants in the lower
quartiles. The level of A1C differed between
the quartiles of 8-oxodG, but no trend
across quartiles was observed. Participants
in the highest quartiles of 8-oxoGuo were
more often nonsmokers, less physically
active, and more often living alone at the
time of diagnosis. Differences in antidiabe-
tes and antihypertension treatment between
the quartiles of 8-oxoGuo were observed
but with no trend across quartiles, except
for the use of diuretics, where those in the
highest quartiles more frequently used diu-
retics (Table 2).
Nucleic acid oxidation and
mortality
The study observation time ranged from26
September 1995 to 1 January 2009, and the
median duration of follow-upwas 9.8 years
(interquartile range 4.2–13.3). During this
period, 654 (61.2%) patients had died; 407
deaths were regarded as diabetes related.
Patients who died between 6-year
follow-up and 1 January 2009 had signif-
icantly higher urinary 8-oxoGuo excre-
tion at 6-year follow-up than survivors
(median 3.89 nmol/mmol creatinine [in-
terquartile range 3.09–4.91] vs. 3.43
nmol/mmol creatinine [2.75–4.16]; P ,
0.0001). In contrast, no signiﬁcant differ-
ence was found for 8-oxodG (2.08 nmol/
mmol creatinine [1.60–2.73] vs. 2.02
nmol/mmol creatinine [1.57–2.63]; P =
0.25).
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Kaplan-Meier analysis estimates of
survival according to quartiles of urinary
8-oxodG and 8-oxoGuo at 6-year follow-
up are shown in Supplementary Fig. 1.
The results of the unadjusted and ad-
justed Cox regression analyses are shown
in Table 3.
At 6-year follow-up, only 8-oxoGuo
was signiﬁcantly associated with mortal-
ity. The unadjusted hazard ratios for all-
cause and diabetes-related mortality of
patients with 8-oxoGuo levels in the
highest quartile compared with those in
the lowest quartile were 2.09 (95% CI
1.62–2.67; P , 0.001) and 1.94 (1.40–
2.69; P , 0.001), respectively. The
multivariate-adjusted hazard ratios for
all-cause and diabetes-related mortality
of patients with 8-oxoGuo levels in the
highest quartile compared with those in
the lowest quartile were 1.86 (1.34–2.58;
P , 0.001) and 1.72 (1.11–2.66; P =
0.02), respectively.
When log8-oxodG and log8-oxoGuo
were considered as continuous covariates,
the results were similar to those described
above (Table 3). The multivariate-adjusted
hazard ratios for all-cause and diabetes-
related mortality per unit increase in log8-
oxoGuo were 1.82 (95% CI 1.36–2.42; P
, 0.001) and 1.64 (1.13–2.37; P = 0.009),
respectively.
Other analyses
We analyzed the signiﬁcance of changes
in the nucleic acid oxidation markers
from diagnosis to 6-year follow-up. For
both 8-oxodG and 8-oxoGuo, ~30% of
the patients in the second and third
quartiles remained in the same quartile
as at diagnosis, whereas this ﬁgure was
~45% for patients in the highest and
lowest quartiles (Table 4). The unad-
justed and multivariate-adjusted hazard
ratios for all-cause mortality of patients
who changed quartile from diagnosis to
6-year follow-up compared with those
who remained in the same quartile are
shown in Table 4.
Table 1dCharacteristics at 6-year follow-up according to quartiles of 8-oxodG
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P*
N 234 235 234 235
8-oxodG level (nmol/mmol creatinine) ,1.59 1.59–2.05 2.06–2.69 .2.69
Male sex 62.0 48.5 49.6 45.1 0.002
Age (years) 66.1 (58.1–74.4) 69.4 (61.1–76.9) 67.7 (58.8–76.9) 71.1 (61.3–78.9) 0.003
Duration of diabetes (years) 5.4 (4.9–6.0) 5.5 (4.9–6.1) 5.5 (4.9–6.0) 5.4 (4.9–6.0) 0.75
Smoking status 0.34
Never 31.8 27.5 37.5 35.9
Previous 38.3 38.7 33.0 32.7
Current 30.0 33.8 29.5 31.4
Physical activity 0.32
Low 30.7 26.7 25.1 34.7
Moderate 61.5 63.8 66.4 59.4
High 7.8 9.5 8.5 5.9
Cohabitation status (living alone) 25.5 29.9 27.0 29.7 0.67
Education (basic) 75.2 80.9 78.2 80.1 0.47
A1C 8.5 (7.7–9.7) 8.7 (7.9–9.8) 8.9 (7.9–9.9) 8.5 (7.4–9.9) 0.046
Total cholesterol (mmol/L) 6.1 (5.3–6.8) 6.2 (5.4–7.0) 5.8 (5.2–6.7) 6.0 (5.1–6.8) 0.017
Fasting triglycerides (mmol/L) 1.92 (1.26–2.66) 1.85 (1.27–2.62) 1.80 (1.17–2.68) 1.69 (1.23–2.43) 0.53
Serum creatinine (mmol/L) 93.0 (83.0–110.0) 91.0 (82.0–103.0) 89.0 (79.0–100.0) 85.5 (77.0–99.0) ,0.001
Urinary albumin (mg/L) 11.9 (5.6–29.1) 10.9 (5.7–25.9) 12.5 (4.9–30.5) 11.8 (5.2–25.2) 0.90
Hypertension† 74.8 74.9 74.4 68.5 0.33
BMI (kg/m2) 28.5 (25.8–32.1) 28.9 (26.0–32.3) 28.7 (25.7–32.7) 27.0 (25.0–29.7) ,0.001
Retinopathy 16.1 17.0 14.8 11.6 0.43
Peripheral neuropathy 25.3 24.1 23.8 29.0 0.56
History of AMI 12.1 10.2 9.4 6.8 0.28
History of stroke 8.6 8.5 6.8 9.8 0.72
Antidiabetes treatment 0.50
Insulin 15.8 11.1 13.3 9.8
Oral antidiabetes treatment 54.3 57.5 58.1 61.3
Diet only 29.9 31.5 28.6 28.9
Antihypertension treatment
Calcium channel blockers 16.3 16.6 13.3 11.5 0.32
ACE inhibitors 19.3 23.4 19.7 17.9 0.49
Diuretics 42.1 38.7 34.6 35.3 0.32
b-Blockers 8.2 6.8 11.1 6.0 0.18
Other antihypertension treatment 2.2 1.3 1.3 1.7 0.86
Lipid-lowering drugs 6.9 3.8 3.4 3.8 0.24
Data are percent or median (interquartile range) unless otherwise indicated. AMI, acute myocardial infarction. *P values are from x2 tests (for categorical data) or from
ANOVA (for continuous data). †Hypertension was deﬁned as systolic/diastolic blood pressure $160/90 mmHg or the use of antihypertension drugs.
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For 8-oxoGuo, there was a clear and
signiﬁcant trend for increased risk in pa-
tients who changed to higher quartiles and
decreased risk in patients who changed to
lower quartiles. This trend was seen for all
quartiles of 8-oxoGuo at diagnosis but was
most pronounced for patients with 8-
oxoGuo in the highest quartile: the un-
adjusted andmultivariate-adjusted hazard
ratios of patients who changed from the
highest to the lowest quartile of 8-oxoGuo
compared with those who remained in the
highest quartile were 0.38 (95% CI 0.16–
0.89) and 0.31 (0.14–0.68), respectively.
For 8-oxodG, this trend was less obvious
and was only signiﬁcant for patients with
8-oxodG in the lowest and highest quar-
tiles at diagnosis.
The ability of 8-oxoGuo and other
biomarkers and risk factors to predict
mortality was evaluated by ROC curves.
The AUC was 0.63 (95% CI 0.59–0.67)
for a model including the traditional
biomarkers in diabetes: A1C, fasting tri-
glycerides, total cholesterol, urinary albu-
min, systolic blood pressure, and BMI.
Adding 8-oxoGuo to this model increased
the AUC to 0.67 (0.64–0.72) (Supple-
mentary Fig. 2). AUCs for a multivariate
modeldincluding all the covariates in
our multivariate Cox proportional haz-
ards regression model with and without
8-oxoGuodwere 0.88 (0.86–0.91) and
0.87 (0.86–0.91), respectively.
CONCLUSIONSdIn this study, we
found that urinary excretion of the RNA
oxidation marker 8-oxoGuo in a freshly
voidedmorning urine sample 6 years after
diagnosis of diabetes independently pre-
dicted all-cause and diabetes-related mor-
tality, whereas the DNA oxidation marker
8-oxodG did not. The prognostic infor-
mation of 8-oxoGuo was independent of
other characteristics of patients with type
Table 2dCharacteristics at 6-year follow-up according to quartiles of 8-oxoGuo
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P*
N 234 234 234 234
8-oxoGuo level
(nmol/mmol creatinine) ,2.94 2.94–3.64 3.65–4.66 .4.66
Male sex 69.2 54.7 44.0 37.6 ,0.001
Age (years) 63.6 (55.3–71.3) 68.2 (59.2–75.9) 70.0 (61.9–77.7) 72.7 (65.8–79.5) ,0.001
Duration of diabetes (years) 5.4 (4.9–5.9) 5.5 (4.8–6.1) 5.4 (4.9–5.9) 5.5 (4.9–6.0) 0.91
Smoking status 0.005
Never 24.1 31.9 34.7 42.1
Previous 38.2 35.4 37.9 31.0
Current 37.7 32.7 27.4 26.9
Physical activity ,0.001
Low 19.7 25.1 32.2 40.0
Moderate 70.9 66.5 59.8 54.0
High 9.4 8.4 7.9 6.1
Cohabitation status (living alone) 15.4 29.4 30.8 36.4 ,0.001
Education (basic) 75.3 78.0 78.3 82.7 0.29
A1C 8.6 (7.8–9.7) 8.5 (7.7–9.6) 8.8 (7.8–10.1) 8.6 (7.7–9.9) 0.47
Total cholesterol (mmol/L) 5.9 (5.2–6.6) 6.1 (5.2–6.9) 6.1 (5.4–6.8) 6.0 (5.2–7.0) 0.64
Fasting triglycerides (mmol/L) 1.67 (1.20–2.45) 1.88 (1.23–2.66) 1.86 (1.24–2.66) 1.80 (1.27–2.65) 0.45
Serum creatinine (mmol/L) 92.0 (85.0–105.0) 89.0 (80.0–103.0) 88.0 (79.0–101.0) 88.0 (78.0–104.5) 0.001
Urinary albumin (mg/L) 11.9 (5.1–26.6) 11.0 (5.1–27.0) 10.2 (5.4–27.5) 13.0 (6.1–30.5) 0.49
Hypertension† 71.4 69.7 76.1 75.2 0.34
BMI (kg/m2) 28.7 (25.8–32.0) 28.1 (25.3–31.9) 28.5 (25.9–32.4) 27.9 (25.1–31.3) 0.30
Retinopathy 14.2 14.5 13.5 17.6 0.66
Peripheral neuropathy 19.9 27.0 28.0 26.9 0.17
History of AMI 10.8 9.0 7.3 11.2 0.45
History of stroke 7.3 7.3 9.4 9.8 0.65
Antidiabetes treatment 0.009
Insulin 17.5 8.6 15.0 8.6
Oral antidiabetes treatment 50.9 62.4 54.7 63.7
Diet only 31.6 29.1 30.3 27.8
Antihypertension treatment
Calcium channel blockers 14.5 11.5 15.5 15.8 0.54
ACE inhibitors 21.8 18.4 26.6 13.7 0.005
Diuretics 34.2 31.2 41.2 43.6 0.018
b-Blockers 9.0 7.3 8.6 7.3 0.86
Other antihypertension
treatment 2.1 0.9 1.3 2.1 0.61
Lipid-lowering drugs 6.0 3.0 5.2 3.9 0.41
Data are percent or median (interquartile range) unless otherwise indicated. AMI, acute myocardial infarction. *P values are from x2 tests (for categorical data) or from
ANOVA (for continuous data). †Hypertension was deﬁned as systolic/diastolic blood pressure $160/90 mmHg or the use of antihypertension drugs.
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2 diabetes that have been linked to mortal-
ity: most importantly, age, sex, A1C, lipids,
urinary albumin excretion, blood pressure,
smoking, and preexisting cardiovascular
disease (14–19).
In addition, we found that changes in
8-oxoGuo from the time of diagnosis to
6-year follow-up were associated with
mortality, with increased risk of death in
patients with an increase and decreased
risk of death in patients with a decrease
in 8-oxoGuo. This ﬁnding supports the
notion that RNA oxidation is not only a
predictor of risk in diabetes but also a risk
factor, i.e., that modiﬁcation of RNA oxi-
dation also modiﬁes risk.
To our knowledge, our population-
based study of diabetic patients is the only
study of the association between urinary
excretion ofmarkers of oxidative stress and
mortality in diabetic patients. As in the
current study, urinary 8-oxoGuo assessed
at the time of diagnosis was shown to be an
independent predictor ofmortality (9). The
association between 8-oxoGuo andmortal-
ity seemed stronger at 6-year follow-up
than at diagnosis. At diagnosis, the risk of
death was ~50% higher among those in the
highest quartile than among those in the
lowest quartile, whereas this ﬁgure was
~90% at 6-year follow-up.
ROC curve analyses showed that
8-oxoGuo added prognostic information
to other established biomarkers in diabetes.
However, in themultivariatemodel includ-
ing all the covariates in our multivariate
Cox proportional hazards regression
model, 8-oxoGuo did not signiﬁcantly im-
prove the predictive accuracy of the model.
RNA oxidation could be an epiphe-
nomenon rather than a contributing path-
ophysiological mechanism, but it would
still function as a marker of generalized
intracellular oxidative stress. However,
the fact that only 8-oxoGuo was shown
to be an independent predictor of mor-
tality suggests that RNA oxidation plays a
more important role in diabetic patients
than DNA oxidation and generalized in-
tracellular oxidative stress. The exact
pathophysiological mechanisms behind
diabetes complications are still elusive. It
has been suggested that mitochondrial
dysfunction, with failure of complete
oxidation leading to overproduction of
superoxide by the mitochondrial electron-
transport chain, plays a key role in the
biochemical abnormalities leading to
vascular complications in diabetes (20).
Superoxide is readily converted into hy-
drogen peroxide through the action of su-
peroxide dismutase, and in the presence of
iron, hydrogen peroxide is reduced to hy-
droxyl radicals by a Fenton reaction. The
highly reactive hydroxyl radicals then ox-
idize DNA and RNA among many other
macromolecules (20). Compared with
DNA, RNA is more prone to oxidative
damage because of its widespread distribu-
tion in close proximity to sites of reactive
oxygen species generation, its single-
stranded nature, and the lesser association
with protecting proteins. Surprisingly, the
role of RNA oxidation in human disease
has only recently been investigated, pre-
dominantly in degenerative brain diseases
(21–30). On the basis of the limited evi-
dence available, we suggest a possible
mechanism by which RNA oxidation
could be involved in the development of
diabetes complications. RNA oxidation is
observed in both mRNA and noncoding
RNA.Oxidized bases onmRNAmay cause
ribosome stalling on the mRNA with pro-
duction of truncated proteins or slow the
translational process, leading to a reduc-
tion in protein expression (31). Since the
noncoding RNAs, which include rRNA,
tRNA, and mRNAs, play critical regula-
tory roles in mRNA translation, oxidation
of these could further negatively affect
the translational process, leading to
smaller quantities of protein overall and/
or defective proteins, which may have
detrimental effects on a variety of distinct
cellular processes that lead to changes in
proliferation and apoptosis (31–33).
Apoptosis plays an important role in
the development of the atherosclerotic
plaque (34), and through this pathway
increased RNA oxidation may be in-
volved in the development of the vas-
cular complications in diabetes. It
should be emphasized that the described
possible mechanism is a suggestion
based on available evidence and that no










Quartile 1 1.0 1.0
Quartile 2 1.01 (0.79–1.30) 0.92 1.02 (0.75–1.38) 0.92
Quartile 3 1.03 (0.81–1.32) 0.80 1.14 (0.84–1.54) 0.40
Quartile 4 1.18 (0.93–1.51) 0.18 1.26 (0.94–1.71) 0.14
Log 8-oxodG 1.20 (0.97–1.48) 0.09 1.27 (0.98–1.64) 0.07
8-oxoGuo
Quartile 1 1.0 1.0
Quartile 2 1.26 (0.97–1.63) 0.09 1.12 (0.82–1.54) 0.48
Quartile 3 1.51 (1.16–1.95) 0.002 1.55 (1.13–2.13) 0.007
Quartile 4 2.09 (1.62–2.67) ,0.001 1.86 (1.34–2.58) ,0.001
Log 8-oxoGuo 2.01 (1.63–2.49) ,0.001 1.82 (1.36–2.42) ,0.001
Diabetes-related mortality
8-oxodG
Quartile 1 1.0 1.0
Quartile 2 0.97 (0.71–1.32) 0.85 1.03 (0.71–1.51) 0.86
Quartile 3 0.90 (0.66–1.23) 0.51 1.07 (0.72–1.58) 0.75
Quartile 4 1.13 (0.84–1.54) 0.42 1.18 (0.79–1.74) 0.42
Log 8-oxodG 1.12 (0.86–1.46) 0.41 1.20 (0.86–1.66) 0.29
8-oxoGuo
Quartile 1 1.0 1.0
Quartile 2 1.40 (1.00–1.94) 0.05 1.31 (0.87–1.96) 0.20
Quartile 3 1.68 (1.21–2.32) 0.002 1.71 (1.13–2.58) 0.01
Quartile 4 1.94 (1.40–2.69) ,0.001 1.72 (1.11–2.66) 0.02
Log 8-oxoGuo 2.00 (1.53–2.61) ,0.001 1.64 (1.13–2.37) 0.009
*Covariates included in themultivariate model were age, sex, diabetes duration, smoking status, cohabitation
status, physical activity, education, BMI, A1C, presence or absence of hypertension and of microalbuminuria
(urinary albumin$15 or.15mg/L), total cholesterol, triglycerides, serum creatinine, presence or absence of
retinopathy and of peripheral neuropathy, history of acute myocardial infarction and stroke, and antidiabetes
treatment.
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Table 4dRelationship between changes in 8-oxodG and 8-oxoGuo from diagnosis to 6-year follow-up and all-cause mortality
Quartile at diagnosis N (%)
Unadjusted
hazard ratio (95% CI)
Multivariate-adjusted
hazard ratio (95% CI)* Ptrend
8-oxodG
Quartile 1 at diagnosis
Follow-up quartile
1 105 (46.7) 1.00 1.00 0.02
2 66 (29.3) 1.41 (0.93–2.14) 1.57 (0.92–2.68)
3 35 (15.6) 1.33 (0.79–2.24) 1.80 (0.92–3.52)
4 19 (8.4) 1.19 (0.60–2.34) 2.29 (1.01–5.20)
Quartile 2 at diagnosis
Follow-up quartile
1 64 (27.6) 1.16 (0.66–2.04) 1.42 (0.84–2.42) 0.71
2 66 (28.5) 1.00 1.00
3 62 (26.7) 0.96 (0.53–1.74) 1.02 (0.57–1.82)
4 40 (17.2) 1.11 (0.58–2.13) 1.43 (0.73–2.78)
Quartile 3 at diagnosis
Follow-up quartile
1 34 (14.5) 1.25 (0.65–2.40) 1.24 (0.73–2.18) 0.70
2 63 (26.8) 1.06 (0.60–1.89) 0.85 (0.49–1.46)
3 74 (31.5) 1.00 1.00
4 64 (27.2) 1.31 (0.76–2.27) 1.26 (0.73–2.18)
Quartile 4 at diagnosis
Follow-up quartile
1 23 (10.0) 0.97 (0.50–1.86) 0.33 (0.14–0.77) 0.04
2 38 (16.5) 1.15 (0.69–1.93) 0.98 (0.55–1.75)
3 60 (26.0) 0.76 (0.46–1.26) 1.30 (0.80–2.10)
4 110 (47.6) 1.00 1.00
8-oxoGuo
Quartile 1 at diagnosis
Follow-up quartile
1 104 (44.6) 1.00 1.00 0.002
2 56 (24.0) 1.40 (0.80–2.47) 0.89 (0.50–1.59)
3 47 (20.2) 1.34 (0.73–2.45) 1.34 (0.75–2.41)
4 26 (11.2) 2.37 (1.20–4.66) 1.59 (0.77–3.30)
Quartile 2 at diagnosis
Follow-up quartile
1 63 (27.6) 0.72 (0.36–1.41) 0.64 (0.35–1.14) 0.02
2 73 (32.0) 1.00 1.00
3 56 (24.6) 1.57 (0.87–2.83) 1.30 (0.71–2.37)
4 36 (15.8) 1.58 (0.79–3.15) 1.11 (0.54–2.25)
Quartile 3 at diagnosis
Follow-up quartile
1 40 (16.9) 1.05 (0.57–1.93 0.84 (0.44–1.59) 0.0002
2 58 (24.5) 0.83 (0.47–1.48) 0.71 (0.40–1.24)
3 72 (30.4) 1.00 1.00
4 67 (28.3) 1.15 (0.67–1.96) 1.17 (0.69–1.96)
Quartile 4 at diagnosis
Follow-up quartile
1 21 (9.5) 0.38 (0.16–0.89) 0.31 (0.14–0.68) ,0.0001
2 44 (19.8) 1.03 (0.62–1.71) 0.55 (0.32–0.92)
3 56 (25.2) 1.19 (0.76–1.87) 0.71 (0.43–1.15)
4 101 (45.5) 1.00 1.00
*Covariates included in the multivariate model were age, sex, diabetes duration, smoking status, cohabitation status, physical activity, education, BMI, A1C, presence
or absence of hypertension and of microalbuminuria (urinary albumin$15 or,15 mg/L), total cholesterol, triglycerides, serum creatinine, presence or absence of
retinopathy and of peripheral neuropathy, history of acute myocardial infarction and stroke, and antidiabetes treatment.
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conclusion regarding a causal relationship
betweenRNAoxidation, vascular complica-
tions, and mortality can be drawn from the
present association.
Important limitations of this study
include the reliance on a single measure-
ment of the nucleic acid oxidation mark-
ers in a morning spot urine sample and
the need to elaborate the potential mech-
anisms underlying our ﬁndings. On the
other hand, the fact that a signiﬁcant
association between 8-oxoGuo and mor-
tality was shown both at diagnosis (9) and
at follow-up and the relation between
changes in RNA oxidation and mortality
support the assumption that the associa-
tion is not a chance ﬁnding. Another lim-
itation is that only BMI was used to
evaluate obesity. However, it has been
shown that waist circumference and
waist-to-hip ratio may be better predic-
tors of mortality than BMI (35). Unfortu-
nately, these anthropometric measures
were not assessed. In addition, glucose
variability, which has been shown to
exhibit a more speciﬁc triggering effect
on oxidative stress than chronic sustained
hyperglycemia (36,37), was not assessed
in the study. Finally, the lack of informa-
tion on diet and consumption of antiox-
idants, which potentially could affect the
level of oxidative stress, should be men-
tioned. The main strengths of our study
include the prospective design, the large
sample size, the long follow-up period,
and the low attrition rate.
The ﬁndings of this study may pro-
vide new insight into the pathophysio-
logical mechanisms responsible for the
development of complications in diabetes
but also indicate that measurement of 8-
oxoGuo could have clinical applications.
In the prevention of complications in
diabetic patients, multivariate risk factor
approaches are used to assess risk (38).
Biomarkers used in these approaches in-
clude A1C, lipids, and urinary albumin.
Our data show that urinary 8-oxoGuo
predicts mortality in type 2 diabetic pa-
tients independent of other conventional
risk factors including these currently used
biomarkers. Measurement of urinary 8-
oxoGuo could therefore provide addi-
tional information about risk that may
be useful for identifying patients who
would beneﬁt the most from intensiﬁed
treatment or speciﬁc treatment strategies.
A multivariate risk factor approach with
the combined use of 8-oxoGuo and other
known risk factors could therefore be use-
ful for improving risk stratiﬁcation of di-
abetic patients. It should be emphasized,
though, that the clinical signiﬁcance of
using this marker is unknown, since the
clinical utility of 8-oxoGuo remains to be
determined.
Although the clinical trials conducted
to date have failed to provide adequate
support for the use of antioxidants in
diabetes, recent studies of bardoxolone
methyl (39), showing beneﬁcial effect on
glomerular ﬁltration rate in type 2 dia-
betic patients, suggest that targeting the
Nrf2 (nuclear factor erythroid 2–related
factor 2) pathway may be a useful strategy
to counteract oxidative stress in diabetes.
Investigating the effect of activators of
Nrf2 on RNA oxidation may provide in-
teresting information that could shed
more light on the role of RNA oxidation
in diabetes. In addition, intervention
studies should be initiated to investigate
the effect of different treatment modalities
of diabetes (e.g., glycemic control, exer-
cise, diet, and weight control) on RNA
oxidation.
Further experimental work is needed
to establish the exact mechanisms respon-
sible for the association between 8-oxoGuo
and mortality in diabetes patients, and
studies should be initiated to evaluate the
potential clinical applications of 8-oxoGuo
as a biomarker in diabetes that could be
used for risk stratiﬁcation, selection of
appropriate therapeutic intervention, or
monitoring response to therapy.
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